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Abstract

Background Comparative outcome data on tricuspid
valve repair (TVr) versus tricuspid valve replacement
(TVR) for severe secondary tricuspid regurgitation (TR) are
limited.
Methods We used a national inpatient sample to assess
in-hospital morbidity and mortality, length of stay and cost
in patients with severe secondary TR undergoing isolated
TVr versus TVR.
Results A total of 1364 patients (national estimate=6757)
underwent isolated tricuspid valve surgery during
the study period, of whom 569 (41.7%) had TVr and
795 (58.3%) had TVR. There was no difference in the
prevalence of major morbidities between the two groups,
except for liver disease and hepatic cirrhosis, which
were more common in the TVR group. Before propensity
matching, in-hospital mortality was similar between
patients who underwent isolated TVr and TVR (8.1% vs
10.8%, p=0.093), but the incidence of postoperative
morbidities differed: TVR was associated with higher
rates of permanent pacemaker implantation and blood
transfusion, while TVr was associated with more acute
kidney injury. After rigorous propensity score matching,
TVR was associated with significantly higher rates of inhospital death (12% vs 6.9%, p=0.009) and permanent
pacemaker implantation (33.7% vs 11.2%, p<0.001).
Postoperative morbidities and length of stay, however,
were not different between the two groups. Nonetheless,
cost of hospitalisation was 16% higher in the TVr group.
Conclusions In patients undergoing isolated surgery for
secondary TR, TVR is associated with higher in-hospital
mortality and need for permanent pacemaker compared
with TVr. Further studies are needed to understand the
impact of the type of surgery on the short-term and longterm mortality in this complex undertreated population.

Secondary tricuspid regurgitation (TR) is the
predominant cause of severe TR in North
America.1 Despite the deleterious effect of
severe TR on long-term outcomes, contemporary data on tricuspid valve (TV) surgery
remain limited.2 This is likely multifactorial
due to modest annual volume of TV surgery,
under-recognition of TV disease, delayed

Key questions

What is already known about this subject?
►► Comparative outcomes data for tricuspid valve re-

pair versus replacement inpatients with severe secondary tricuspid regurgitation are limited.

What does this study add?
►► In patients with severe secondary tricuspid regur-

gitation, tricuspid valve replacement is associated
with significantly higher rates of in-hospital death
(12% vs 6.9%, p=0.009) and permanent pacemaker
implantation (33.7% vs 11.2%, p<0.001).

How might this impact on clinical practice?
►► In patients with severe secondary tricuspid regurgi-

tation and suitable anatomy, tricuspid repair is associated with at least comparable outcomes compared
with valve replacement.
►► However, further comparative studies are needed to
assess long-term outcomes of patients undergoing
repair versus replacement.

clinical presentation, high prevalence of
comorbidities in these patients, and lack of
consensus on the approach and timing of TV
surgery.3 Once the patient is referred for TV
surgery for severe TR, the decision to repair
or replace the valve is also complex and
depends on the patient’s age and comorbidities, the degree of right ventricular dilatation
and dysfunction, the need for a concomitant
procedure, and surgical expertise. Comparative outcome data on tricuspid valve repair
(TVr) versus tricuspid valve replacement
(TVR) for secondary TR are limited. A recent
meta-analysis by Choi et al4 suggested more
favourable outcomes with TVr, but this was
confounded with the inclusion of patients
with primary TR and concomitant operations. The purpose of this study is to assess
in-hospital morbidity and mortality, length of
stay and cost in patients with severe secondary
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Methods
The Nationwide Inpatient Sample (NIS)3 was used to
derive patient-relevant information between January
2003 and December 2014. The NIS is the largest, publicly
available, all-payer administrative claims-based database
and contains information about patient discharges from
~1000 non-federal hospitals in 45 states. It contains clinical
and resource use information on 5–8 million discharges
annually, with safeguards to protect the privacy of individual patients, physicians and hospitals. The NIS shares
certain similarities with the Medicare database, including
the same International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) coding system
for procedures and diagnoses. Contrary to the Medicare
database, the NIS includes all payers and patients across
all ages. These data are stratified to represent ~20% of US
inpatient hospitalisations across different hospital and
geographical regions (random sample). The national
estimates (NE) represent a calculated estimate of the total
(100%) US hospitalised population. This is calculated
using the Agency for Healthcare Research and Quality
sampling and weighting method. Outcomes analysis was
performed using the actual 20% sample available in the
NIS, whereas the trend analysis was performed using the
NE.
Patients aged 18 years and older who underwent TVR
(ICD-9-CM procedure code 35.27 and 35.28) and TVr
(ICD-9-CM code 35.14) during the study period were
identified. To identify patients with secondary TR, those
with congenital TV disease (ICD-9-CM codes 764.1,
746.2, 745.4 and 746.89) or those with infective endocarditis (ICD-9-CM code 571.2) were excluded. Patients
who underwent redo TV surgery were also excluded
(ICD-9-CM codes 35.20 and 35.21). To eliminate potential impact of concurrent cardiac surgery on outcomes,
patients who underwent a concomitant valve surgery,
coronary bypass grafting or surgical ablation for atrial
fibrillation (maze procedure) were excluded. A flow
chart of the study is provided in figure 1.
Patients who underwent isolated TV surgery for severe
secondary TR were divided into two groups according to
the surgical approach (group 1, isolated TVr; and group
2, isolated TVR). We then performed a comparative analysis between the outcomes of isolated TVr and TVR in
patients with severe secondary TR. To account for potential confounding factors and reduce the effect of selection
bias, a propensity score matching model was developed
using logistic regression to derive two matched groups
for comparative outcomes analysis. Patients who underwent isolated TVr or isolated TVR were entered into a
nearest neighbour 1:1 variable ratio, parallel, balanced
propensity matching model using a calliper of 0.01 to
attain two pairs of well-matched cohort for outcomes
analysis. Propensity scores were derived from 41 hospital,
2

clinical and demographic covariates, including the Elixhauser Comorbidity Index. The primary endpoint was
in-hospital death. The secondary outcomes included
postoperative morbidities, length of stay, hospital charges
and discharge disposition.
Patient-relevant descriptive statistics are presented as
frequencies with percentages for categorical variables
and as means with SD for continuous variables. Baseline characteristics were compared between the groups
using a Pearson’s χ2 test for categorical variables and
an independent-samples t-test for continuous variables.
A Cochran-Armitage test was used to evaluate trends in
isolated TVr and isolated TVR in patients with severe
secondary TR. Matched categorical variables were
presented as frequencies with percentages and compared
using McNemar’s test. Matched continuous variables were
presented as means with SD and compared using a pair
ed-samples t-test. All statistical analyses were performed
using SPSS V.24 and R V.3.3.1.
Results
A total of 1364 actual reported cases (NE=6757) underwent isolated TV surgery during the study period, of
whom 569 (41.7%) had TVr and 795 (58.3%) had
TVR (figure 2). Compared with patients who had TVr,
those who underwent TVR were older (56±17 vs 54±18,
p=0.02), were women (57.6% vs 51.1%, p=0.018) and
were Caucasians (71.9% vs 64.6%, p=0.018). There was
no difference in the prevalence of major morbidities
between the two groups (table 1), except for liver disease
and hepatic cirrhosis, which were more common in the
TVR group (11.1% vs 3.7% and 5.8% vs 1.4%, respectively, p<0.001 for all). Surgery was frequently performed
during a non-elective admission in both groups but more
commonly for TVr (45.8% vs 35%, p<0.001).
Before propensity score matching, in-hospital mortality
was similar between patients who underwent isolated
TVr or TVR (8.1% vs 10.8%, p=0.093), but the incidence
of postoperative morbidities differed: TVR was associated with a threefold higher rate of permanent pacemaker implantation (34.1% vs 10.9%, p<0.001) and a
trend towards more blood transfusion (37.6% vs 32.7%,
p=0.06), while TVr was associated with more acute kidney
injury (33.7% vs 27.8%, p=0.018). Nonetheless, the need
for renal replacement therapy following surgery was not
different between the two groups (4.4% vs 5.5% following
TVr vs TVR, p=0.34). Patients who had TVr had longer
hospitalisations (23±26 vs 19±24, p=0.013), but both
groups had comparable rates of non-home discharges
(table 2). Temporal trends in in-hospital mortality
following isolated TVR and TVr are shown in (online
supplementary figure 1).
After rigorous propensity score matching, no significant differences in baseline characteristic were observed
(table 1). In propensity-matched patients, TVR was associated with significantly higher rates of in-hospital death
(12% vs 6.9%, p=0.009) and permanent pacemaker
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implantation (33.7% vs 11.2%, p<0.001). Postoperative morbidities and length of stay, however, were not
different between the two groups (table 2). Nonetheless,
cost of hospitalisation was 16% higher in the TVr group.
Discussion
The following are the main findings of the present investigation: (1) Isolated tricuspid surgery for secondary
TR is infrequently performed in the USA. (2) Patients
undergoing isolated TVR versus TVr have similar baseline characteristics, with the exception of chronic liver
disease, which was more prevalent in the TVR group. (3)
In propensity-matched cohorts of patients, isolated TVR
is associated with 74% higher incidence of in-hospital
mortality and 300% higher rate of permanent pacemaker
implantation compared with isolated TVr. Although
Alkhouli M, et al. Open Heart 2018;5:e000878. doi:10.1136/openhrt-2018-000878

length of stay was comparable in both groups, cost of
hospitalisation was 16% higher after TVr than after TVR.
It is estimated that 1.6 million patients in the USA
suffer from moderate to severe TR.5 6 In the Framingham
Study moderate or severe TR was present in 1.5% of men
and 5.6% of women >70 years of age.7 The prevalence
is higher in patients with concomitant valvular disease
or cardiomyopathy. Moderate to severe TR is found in
30%–50% of patients with severe mitral regurgitation,
12%–25% of patients with severe aortic stenosis and
19% of patients with congestive heart failure.8–12 The
percentage of patients with symptomatic TR is uncertain
and remains difficult to estimate given the high prevalence of other potential sources of symptoms and comorbidities in these patients.13 Nonetheless, the current
study confirms that only a small fraction of patients at
3
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Figure 1 Study flow chart. NE, national estimate; TR, tricuspid regurgitation; TVr, tricuspid valve repair; TVR, tricuspid valve
replacement.
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risk undergo isolated TV surgery in the USA. Among
these patients, however, a slight majority undergoes TVR
(58.3%) and the remainder undergo TVr.
Despite the relatively young age of patients in this
cohort (55±17 years), major comorbidities were common
(hypertension 43%, diabetes 18%, atrial fibrillation
45%, coagulopathy 28% and chronic renal disease
22%). Although both groups had comparable baseline
risk profiles, the TVR group had higher prevalence of
chronic liver disease. This is important and this could be
related to a more advanced right ventricular disease and
subsequent congestive hepatopathy, both are likely to
contribute to worse short-term and long-term outcomes
in the TVR group.
The decision of whether to repair or replace the TV is
complex and depends on multiple factors: (1) timing of
surgery, (2) anatomical factors and (3) clinical expertise.
Unlike aortic or mitral valve disease, where the timing
of operation may often be driven by symptoms, many
patients with severe TR remain symptomatic for prolonged
periods before being referred to surgical correction. At
this point, patients have often developed severe tethering
and marked right ventricular dysfunction that may inevitably impact surgical outcomes. Anatomical factors, such
as the degree of annular dilatation and leaflet tethering,
play a significant role in determining the surgical therapy.
Although TVr is usually the preferred approach in order
to minimise bypass time, TVR is frequently needed in
cases of extreme annular dilatation or leaflet abnormality (such as in pacemaker-related TR)14 15 Patient
choice, compliance and clinical expertise also influence
the choice of TVr versus TVR. Bioprosthetic valve degeneration and mechanical valve thrombosis continue to
generate much debate and may impact the decision to
repair or replace in patients with compliance issues.16
4

Similarly, experience with repair techniques is key to
minimise risk of recurrence.17 The lack of such experience may also affect decision making on the surgical
approach. Hence, selection bias will remain a significant
confounder in any retrospective investigations pertaining
to TV surgery. Notably, a high percentage of patients had
bioprosthetic valve implantation in this study, likely due
to concerns about non-compliance with lifelong anticoagulation. Although we performed vigorous propensity
score matching to account for differences in baseline
risk profiles and hospital characteristics, the above-mentioned factors should be considered when interpreting
the current study results.
In propensity-matched groups, TVR was associated
with higher in-hospital mortality compared with TVr.
Prior comparative studies on TVr versus TVR yielded
conflicting data likely due to design issues and the inclusion of heterogeneous groups of patients with various
TR aetiologies.18–27 A recent comprehensive meta-analysis pooled data from 17 studies and compared TVr
versus TVR in patients with severe TR for the primary
endpoint of all-cause mortality.4 This meta-analysis
showed that TVR was associated with higher mortality
compared with TVr (HR 1.59, 95% CI 1.26 to 2.00)
(I2=62%). A subanalysis including only studies with
predominantly patients with secondary TR revealed
that TVR remained associated with higher odds of
all-cause mortality (HR 1.39, 95% CI 1.04 to 1.86). This
is consistent with the current findings of a 74% higher
risk of postoperative mortality following TVR versus
TVr. The contribution of right ventricular dysfunction,
duration of the TV disease, and surgical volume and
techniques on this excess mortality in the TVR group
cannot be ascertained due to the lack of data on disease
duration or echocardiographic findings in the NIS and
Alkhouli M, et al. Open Heart 2018;5:e000878. doi:10.1136/openhrt-2018-000878
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figure 2 Temporal trend of isolated tricuspid valve surgery for secondary tricuspid regurgitation in the USA between 2003
and 2014. TVr, tricuspid valve repair; TVR, tricuspid valve replacement. x axis, year; y axis, number of cases (weighted national
estimates).

Cardiac surgery

Unmatched cohorts
Baseline
characteristics

TVr
n=569

TVR
n=795

Matched cohorts
P values

TVr
n=475

TVR
n=475

P values

Age (years), mean
(SD)
Female, n (%)

54 (18)

56 (17)

0.021

55 (18)

55 (17)

0.818

291 (51.1)

458 (57.6)

0.018

259 (54.5)

259 (54.5)

0.99

White race

307 (64.6)

466 (71.9)

0.018

306 (64.4)

308 (64.8)

0.76

Black race

99 (20.8)

88 (13.6)

83 (17.5)

75 (15.8)

Hispanic race

35 (7.4)

49 (7.6)

39 (8.2)

37 (7.8)

Medical comorbidity
  Hypertension

241 (42.4)

346 (44)

0.56

205 (43.2)

0.838

  Diabetes

103 (18.1)

140 (17.6)

0.815

85 (17.9)

84 (17.7)

0.99

81 (14.2)

106 (13.3)

0.633

67 (14.1)

66 (13.9)

0.99

210 (44.2)

201 (42.3)

0.582

 Chronic lung
disease

209 (44)

  Atrial fibrillation/
flutter

243 (42.7)

366 (46)

0.222

  Anaemia

120 (21.1)

175 (22)

0.683

99 (20.8)

99 (20.8)

0.99

  Coagulopathy

155 (27.3)

219 (27.9)

0.816

129 (27.2)

131 (27.6)

0.943

  Conduction
abnormalities

17 (3)

23 (2.9)

0.919

11 (2.3)

12 (2.5)

0.99

  Vascular disease

37 (6.5)

54 (6.8)

0.832

33 (6.9)

29 (6.1)

0.688

 Chronic renal
disease

125 (22)

183 (23)

0.647

100 (21.1)

101 (21.3)

0.99

  Haemodialysis

17 (3)

36 (4.5)

0.147

17 (3.6)

18 (3.8)

0.99

 Coronary artery
disease

84 (14.8)

98 (12.3)

0.192

65 (13.7)

66 (13.9)

0.99

 Liver disease

21 (3.7)

87 (11.1)

<0.001

20 (4.2)

27 (5.7)

0.265

 Liver cirrhosis

8 (1.4)

46 (5.8)

<0.001

8 (1.7)

13 (2.7)

0.267

  Teaching hospital 489 (86.2)

682 (86)

0.899

410 (86.3)

406 (85.5)

0.775

 Large hospital size 494 (87.1)

650 (82)

0.033

406 (85.5)

400 (84.2)

0.342

Hospital
characteristics

 Rural location

6 (1.1)

Non-elective
admission

260 (45.8)

Mechanical
prosthesis

0 (0)

9 (1.1)

0.894

6 (1.3)

6 (1.3)

0.99

278 (35)

<0.001

187 (39.4)

179 (37.7)

0.622

305 (38.4)

<0.001

0 (0)

203 (42.7)

<0.001

Primary payer, n (%)

0.019

0.595

  Medicare/
Medicaid

315 (55.4)

506 (63.6)

275 (57.9)

271 (57.1)

 Private, including
HMO

214 (37.6)

240 (30.2)

169 (35.6)

168 (35.4)

18 (3.2)

25 (3.1)

15 (3.2)

16 (3.4)

  Self-pay/no
charge/other
Median income, n (%)
  1.0–25th
percentile
  2.26–50th
percentile

0.565

0.437

159 (28.7)

200 (25.9)

135 (28.4)

126 (26.5)

128 (23.1)

196 (25.4)

113 (23.8)

127 (26.7)
Continued
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Unmatched cohorts

Matched cohorts

Baseline
characteristics

TVr
n=569

TVR
n=795

TVr
n=475

TVR
n=475

  3.51–75th
percentile
  4.76–100th
percentile

137 (24.7)

184 (23.8)

111 (23.4)

105 (22.1)

130 (23.5)

193 (25)

116 (24.4)

117 (24.6)

P values

P values

HMO, health maintenance organisation;TVR, tricuspid valve replacement;TVr, tricuspid valve repair.

the inability to perform a meaningful volume-outcomes
analysis due to the very low volume of TV surgery in
the USA overall. Some of these factors, however, have
been shown to play an important role on the operative
mortality following TV surgery. The role of routine
surveillance and early intervention was demonstrated
in a Korean registry of 106 patients with rheumatic
valvular disease and prior left-sided valve operations.

These patients had worsening TR during follow-up and
subsequently underwent TVR (50%) and TVr (50%),
which were performed with a very low early operative
mortality (1.9%).28 Similar low operative mortality of
TVR and TVr has been demonstrated in other series.25 29
In the study by Sung et al,29 the authors suggested their
liberal use of modified ultrafiltration (95% of patients)
was essential in reducing postoperative mortality. The

Table 2 In-hospital outcomes of unmatched and propensity -matched patients undergoing isolated tricuspid repair versus
replacement, 2003–2014
Unmatched cohorts
Clinical
outcomes

TVr
n=569

Matched cohorts

TVR
n=795

P values

TVr
n=475

TVR
n=475

P values

In-hospital death
Permanent
pacemaker

46 (8.1)
62 (10.9)

86 (10.8)
271 (34.1)

0.093
<0.001

33 (6.9)
53 (11.2)

57 (12)
160 (33.7)

0.009
<0.001

Stroke

13 (2.3)

10 (1.3)

0.146

9 (1.9)

7 (1.5)

0.804

192 (33.7)

221 (27.8)

0.018

146 (30.7)

141 (29.7)

0.773

Acute kidney injury
New dialysis
Blood transfusion

25 (4.4)

44 (5.5)

0.343

21 (4.4)

30 (6.3)

0.253

186 (32.7)

299 (37.6)

0.06

159 (33.5)

170 (35.8)

0.493

Cardiac tamponade

14 (2.5)

9 (1.1)

0.06

9 (1.9)

5 (1.1)

0.424

Pneumonia

49 (8.6)

54 (6.8)

0.21

36 (7.6)

32 (6.7)

0.708

Prolonged ventilation

42 (7.4)

45 (5.7)

0.2

29 (6.1)

37 (7.8)

0.389

16 (2)

0.166

5 (1.1)

12 (2.5)

0.143

20 (2.5)

0.112

16 (3.4)

17 (3.6)

0.99

6 (0.8)

0.149

7 (1.5)

5 (1.1)

0.754

Wound infection
Pulmonary embolism
Deep venous
thrombosis

6 (1.1)
23 (4)
9 (1.6)

Discharge status,
n (%)

0.113

 Discharged home

408 (71.8)

557 (70.2)

348 (73.3)

324 (68.2)

0.003

 Discharged SNF/
NH/IC

114 (20.1)

147 (18.5)

94 (19.8)

92 (19.4)

0.801

Length of stay (days),
mean (SD)

23 (26)

19 (24)

0.013

21 (26)

21 (28)

0.114

Postoperative length
of stay

18 (21)

15 (20)

0.027

16 (22)

15 (20)

0.496

483 (84.9)

690 (86.8)

0.317

395 (83.2)

413 (86.9)

0.018

Length of stay >5
days
Cost, mean (SD)

$120 849 ($123 772) $84 637 ($8300)

<0.001

$106 143 ($108 803) $91 316 ($86 768) <0.001

IC, intermediate care;NH, nursing home;SNF, skilled nursing facility;TVR, tricuspid valve replacement;TVr, tricuspid valve repair.
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Limitations
This study has several limitations. Although this is
the largest nationwide study examining comparative
outcomes of TVr versus TVR in patients with severe
secondary TR, the results should be interpreted in
the context of its limitations. (1) The NIS is a hospital
claims database derived from ICD-9-CM codes and is
therefore prone to coding inconsistencies. However,
quality control measures are embedded in the Agency
Alkhouli M, et al. Open Heart 2018;5:e000878. doi:10.1136/openhrt-2018-000878

for Healthcare Research and Quality methodology to
minimise these issues. In addition, the hard clinical
endpoints in this study are difficult to miscode (death,
pacemaker implantation, discharge status and so on).
(2) We intended to study patients with secondary TR,
and hence we excluded those with congenital heart
disease and endocarditis. However, we cannot ascertain
that these exclusion criteria were sufficient to identify
a pure cohort of secondary TR. (3) A major limitation
of this study is the inability to capture relevant data
related to the nature and stage of TV disease (right
ventricular dimension and function, pulmonary artery
pressure, aetiology and duration of TV disease, left
ventricular ejection fraction, and so on). We applied
several layers of exclusions to arrive at a pure secondary
TR population, but the lack of granular haemodynamic
and echocardiographic data can possibly confound the
results of the study, such as cost assessment. (4) Details
on the urgency of surgery, surgical repair or replacement techniques, perioperative medications and ventilation management, and long-term outcomes beyond
hospital discharge are not available in the NIS. (5) The
underlying mechanism of severe TR in a non-negligible
number of patients undergoing TVR is pacemaker-related TV disease. In these patients the surgery might
include removal and reimplantation of permanent
pacemaker leads, and hence this can potentially falsely
increase the rate of permanent pacemaker implantation in the TVR group.

Conclusions
Compared with TVR, TVr is associated with at least
comparable in-hospital outcomes in patients with
suitable anatomy for valve repair. Further studies are
needed to understand the differential impact of the type
of surgery on the short-term and long-term mortality in
this complex undertreated population.
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favourable effects of modified ultrafiltration (decreasing
myocardial oedema, improving left ventricular function and improving pulmonary function compliance)
have been demonstrated in non-TV cardiac surgical
operations but can be quite useful in patients with TV
disease due to the higher prevalence of right ventricular failure and pulmonary hypertension.29–31 Further
studies are required to assess the impact of early operations, surgical techniques and various postoperative
management strategies on the outcomes of TV surgery
in the contemporary era.
Major postoperative complications were not significantly different between the two groups, with the
exception of the rate of permanent pacemaker implantation, which was threefold higher following TVR
versus TVr. Similar findings were reported in prior
smaller studies.32 33 Further studies are needed to
assess the potential adverse impact of permanent pacemaker implantation on long-term outcomes in these
patients, especially given that one-third of patients
undergoing TVR received a permanent pacemaker
prior to discharge. A study by Jokinen et al32 showed
that patients who received permanent pacemakers
following TVR experienced a higher rate of thromboembolic complications and impaired quality of life
during long-term follow-up. Hospital length of stay and
frequency of non-home discharges were similar between
the two groups. The modestly increased cost with TVr
was therefore unexpected, particularly with the much
lower rate of pacemaker implantation in this group. We
speculated the following reasons to have contributed
to this cost difference: (1) The TVr group had lower
in-hospital mortality and longer length of stay. The
excess number of death in the TVR group might have
contributed to the lesser cost as these patients would
have incurred more cost should have they survived to
longer hospital stays. (2) The TVr group had higher
incidence of patients admitted non-electively and hence
they possibly incurred additional costs associated with
emergency room charges, early diagnostic testing and
so on, which might have played a role in the cost difference between TVR and TVr. (3) The difference in cost,
although statistically significant, is modest and may be
affected by unmeasured confounders that are difficult
to ascertain in administrative databases. Nonetheless,
further studies are needed to elucidate the underlying
aetiology of this increased cost, such as the potential
influence of right ventricular failure.
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